Intelligence Feed event · Macro · 2026-09-03

    NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data

    Question

    NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data

    Direct answer

    Revolution Medicines announced the publication of Phase 1/2 clinical results for daraxonrasib in the New England Journal of Medicine. The drug is targeting patients with previously treated RAS-mutant non-small cell lung cancer. The trial demonstrated a 42% objective response rate and a median overall survival of 16.0 months, validating targeted small molecule pan-RAS inhibition.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/nejm-publishes-revolution-medicines-phase-1-2-lung-cancer-data-ed9d2f

    MACRO
    NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data
    Revolution Medicines announced the publication of Phase 1/2 clinical results for daraxonrasib in the New England Journal of Medicine. The drug is targeting patients with previously treated RAS-mutant non-small cell lung cancer. The trial demonstrated a 42% objective response rate and a median overall survival of 16.0 months, validating targeted small molecule pan-RAS inhibition.
    RVMD
    Impact
    65
    SEP 3
    SIG
    92%
    RVMD
    NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer Data
    Revolution Medicines announced the publication of Phase 1/2 clinical results for daraxonrasib in the New England Journal of Medicine. The drug is targeting patients with previously treated RAS-mutant non-small cell lung cancer. The trial demonstrated a 42% objective response rate and a median overall survival of 16.0 months, validating targeted small molecule pan-RAS inhibition.
    → Peer-reviewed clinical validation in NEJM increases probability of regulatory approval, boosting risk-adjusted net present value for RVMD oncology pipeline.
    Impact
    Revolution Medicines announced the publication of Phase 1/2 clinical results for daraxonrasib in the New England Journal of Medicine. The drug is targeting patients with previously treated RAS-mutant non-small cell lung cancer. The trial demonstrated a 42% objective response rate and a median overall survival of 16.0 months, validating targeted small molecule pan-RAS inhibition.
    Affected
    RVMD
    Transmission
    Peer-reviewed clinical validation in NEJM increases probability of regulatory approval, boosting risk-adjusted net present value for RVMD oncology pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDclinical pipeline de-risking and commercial asset valuationUp1-5dNEJM publication showed 42% ORR and 16.0 months median OS in NSCLC trial.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month